MannKind (MNKD) Stock Price, News & Analysis

Company Overview

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Key Stats

• Today's Range: $4.66 to $4.93
• 50-Day Range: $4.44 to $5.77
• 52-Week Range: $4.11 to $7.63
• Volume: 1.89 million shs
• Average Volume: 2.39 million shs
• Market Capitalization: $1.49 billion
• P/E Ratio: 70.14
• Dividend Yield: N/A
• Price Target: $9.56
• Consensus Rating: Buy

MannKind Stock Analysis - MarketRank™

MannKind scored higher than 63% of companies evaluated by MarketBeat, and ranked 527th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

MannKind has received a consensus rating of Buy. The company's average rating score is 3.22, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

MannKind has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 130.00%

Earnings Growth

Earnings for MannKind are expected to grow by 130.00% in the coming year, from $0.10 to $0.23 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MannKind is 70.14, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.89.

Price to Earnings Ratio vs. Sector

The P/E ratio of MannKind is 70.14, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 22.45.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.87% of the float of MannKind has been sold short.

Short Interest Ratio / Days to Cover

MannKind has a short interest ratio ("days to cover") of 12.9, which indicates bearish sentiment.

Change versus previous month

Short interest in MannKind has recently decreased by 8.41%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MannKind does not currently pay a dividend.

Dividend Growth

MannKind does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

8.87% of the float of MannKind has been sold short.

Short Interest Ratio / Days to Cover

MannKind has a short interest ratio ("days to cover") of 12.9, which indicates bearish sentiment.

Change versus previous month

Short interest in MannKind has recently decreased by 8.41%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 1.70

News Sentiment

MannKind has a news sentiment score of 1.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for MannKind this week, compared to 4 articles on an average week.

Search Interest

Only 2 people have searched for MNKD on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

3 people have added MannKind to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MannKind insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.00% of the stock of MannKind is held by insiders.

Percentage Held by Institutions

49.55% of the stock of MannKind is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MNKD Stock Analysis - Frequently Asked Questions

How have MNKD shares performed this year?

MannKind's stock was trading at $6.43 at the start of the year. Since then, MNKD shares have decreased by 23.6% and is now trading at $4.91.
View the best growth stocks for 2025 here.

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) issued its quarterly earnings data on Wednesday, February, 26th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.03. The biopharmaceutical company had revenue of $76.78 million for the quarter, compared to the consensus estimate of $74.99 million. MannKind had a net margin of 8.07% and a negative trailing twelve-month return on equity of 17.74%.
Read the conference call transcript.

Who are MannKind's major shareholders?

MannKind's top institutional investors include 180 Wealth Advisors LLC (0.72%), Bank of New York Mellon Corp (0.25%), Rhumbline Advisers (0.13%) and Hennion & Walsh Asset Management Inc. (0.08%). Insiders that own company stock include Michael Castagna, Steven B Binder, Stuart A Tross, David Thomson and Alejandro Galindo.
View institutional ownership trends.

How do I buy shares of MannKind?

Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MannKind own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MannKind investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Bausch Health Companies (BHC), Intel (INTC) and Netflix (NFLX).

Company Calendar

• Last Earnings: 2/26/2025
• Today: 4/29/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MNKD
• CIK: 899460
• Web: www.mannkindcorp.com
• Phone: (818) 661-5000
• Fax: 661-775-2081
• Employees: 400
• Year Founded: 1991

Price Target and Rating

• Average Stock Price Target: $9.56
• High Stock Price Target: $12.00
• Low Stock Price Target: $6.50
• Potential Upside/Downside: +99.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.22
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.10
• Trailing P/E Ratio: 68.46
• Forward P/E Ratio: 47.85
• P/E Growth: N/A
• Net Income: $-11,940,000.00
• Net Margins: 8.07%
• Pretax Margin: 9.37%
• Return on Equity: -17.74%
• Return on Assets: 8.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.54
• Quick Ratio: 4.17

Sales & Book Value

• Annual Sales: $285.50 million
• Price / Sales: 5.09
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.91) per share
• Price / Book: -5.26

Miscellaneous

• Outstanding Shares: 303,845,000
• Free Float: 267,505,000
• Market Cap: $1.45 billion
• Optionable: Optionable
• Beta: 1.22